vs
Side-by-side financial comparison of Karyopharm Therapeutics Inc. (KPTI) and Ouster, Inc. (OUST). Click either name above to swap in a different company.
Ouster, Inc. is the larger business by last-quarter revenue ($62.2M vs $34.1M, roughly 1.8× Karyopharm Therapeutics Inc.). On growth, Ouster, Inc. posted the faster year-over-year revenue change (106.6% vs 11.6%). Over the past eight quarters, Ouster, Inc.'s revenue compounded faster (54.8% CAGR vs 1.4%).
Ouster, Inc. is an American lidar technology company headquartered in San Francisco, California. It builds high-resolution, digital 3D lidar sensors for use in autonomous vehicles, industrial, robotics, drones, mapping, defense, and security systems.
KPTI vs OUST — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $34.1M | $62.2M |
| Net Profit | $-102.2M | — |
| Gross Margin | — | 60.2% |
| Operating Margin | -52.4% | 1.5% |
| Net Margin | -299.9% | — |
| Revenue YoY | 11.6% | 106.6% |
| Net Profit YoY | -232.0% | — |
| EPS (diluted) | $-7.02 | $0.10 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $34.1M | $62.2M | ||
| Q3 25 | $44.0M | $39.5M | ||
| Q2 25 | $37.9M | $35.0M | ||
| Q1 25 | $30.0M | $32.6M | ||
| Q4 24 | $30.5M | $30.1M | ||
| Q3 24 | $38.8M | $28.1M | ||
| Q2 24 | $42.8M | $27.0M | ||
| Q1 24 | $33.1M | $25.9M |
| Q4 25 | $-102.2M | — | ||
| Q3 25 | $-33.1M | $-21.7M | ||
| Q2 25 | $-37.3M | $-20.6M | ||
| Q1 25 | $-23.5M | $-22.0M | ||
| Q4 24 | $-30.8M | — | ||
| Q3 24 | $-32.1M | $-25.6M | ||
| Q2 24 | $23.8M | $-23.9M | ||
| Q1 24 | $-37.4M | $-23.8M |
| Q4 25 | — | 60.2% | ||
| Q3 25 | — | 42.1% | ||
| Q2 25 | — | 45.2% | ||
| Q1 25 | — | 41.3% | ||
| Q4 24 | — | 43.8% | ||
| Q3 24 | — | 38.3% | ||
| Q2 24 | — | 33.7% | ||
| Q1 24 | — | 28.6% |
| Q4 25 | -52.4% | 1.5% | ||
| Q3 25 | -34.6% | -61.4% | ||
| Q2 25 | -64.3% | -76.5% | ||
| Q1 25 | -110.8% | -73.0% | ||
| Q4 24 | -102.4% | -85.1% | ||
| Q3 24 | -67.8% | -98.0% | ||
| Q2 24 | -65.7% | -93.6% | ||
| Q1 24 | -101.9% | -99.5% |
| Q4 25 | -299.9% | — | ||
| Q3 25 | -75.2% | -55.0% | ||
| Q2 25 | -98.2% | -58.8% | ||
| Q1 25 | -78.2% | -67.5% | ||
| Q4 24 | -100.8% | — | ||
| Q3 24 | -82.7% | -91.1% | ||
| Q2 24 | 55.6% | -88.4% | ||
| Q1 24 | -112.8% | -91.9% |
| Q4 25 | $-7.02 | $0.10 | ||
| Q3 25 | $-3.82 | $-0.37 | ||
| Q2 25 | $-4.32 | $-0.38 | ||
| Q1 25 | $-2.77 | $-0.42 | ||
| Q4 24 | $-2.33 | $-0.46 | ||
| Q3 24 | $-3.85 | $-0.54 | ||
| Q2 24 | $-2.97 | $-0.53 | ||
| Q1 24 | $-4.85 | $-0.55 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $60.5M | $208.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-292.9M | $261.7M |
| Total Assets | $108.4M | $349.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $60.5M | $208.6M | ||
| Q3 25 | $37.7M | $244.5M | ||
| Q2 25 | $38.7M | $226.5M | ||
| Q1 25 | $38.8M | $168.2M | ||
| Q4 24 | $62.5M | $172.0M | ||
| Q3 24 | $72.8M | $151.4M | ||
| Q2 24 | $84.8M | $184.2M | ||
| Q1 24 | $30.6M | $187.8M |
| Q4 25 | $-292.9M | $261.7M | ||
| Q3 25 | $-269.3M | $247.4M | ||
| Q2 25 | $-238.9M | $221.0M | ||
| Q1 25 | $-205.9M | $167.9M | ||
| Q4 24 | $-186.0M | $180.9M | ||
| Q3 24 | $-159.6M | $171.7M | ||
| Q2 24 | $-132.1M | $170.6M | ||
| Q1 24 | $-169.0M | $167.2M |
| Q4 25 | $108.4M | $349.5M | ||
| Q3 25 | $96.2M | $353.8M | ||
| Q2 25 | $104.9M | $321.8M | ||
| Q1 25 | $127.7M | $268.6M | ||
| Q4 24 | $164.4M | $276.1M | ||
| Q3 24 | $189.5M | $255.2M | ||
| Q2 24 | $214.0M | $309.9M | ||
| Q1 24 | $204.5M | $317.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-11.8M | $-15.4M |
| Free Cash FlowOCF − Capex | — | $-37.2M |
| FCF MarginFCF / Revenue | — | -59.8% |
| Capex IntensityCapex / Revenue | 0.0% | 35.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-64.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-11.8M | $-15.4M | ||
| Q3 25 | $-5.9M | $-18.3M | ||
| Q2 25 | $-18.7M | $-1.3M | ||
| Q1 25 | $-39.0M | $-4.9M | ||
| Q4 24 | $-25.8M | $-2.6M | ||
| Q3 24 | $-19.5M | $-3.8M | ||
| Q2 24 | $-38.5M | $-21.6M | ||
| Q1 24 | $-43.7M | $-5.7M |
| Q4 25 | — | $-37.2M | ||
| Q3 25 | — | $-20.0M | ||
| Q2 25 | — | $-2.2M | ||
| Q1 25 | — | $-5.4M | ||
| Q4 24 | $-25.9M | $-4.0M | ||
| Q3 24 | — | $-4.3M | ||
| Q2 24 | — | $-22.0M | ||
| Q1 24 | $-43.9M | $-7.1M |
| Q4 25 | — | -59.8% | ||
| Q3 25 | — | -50.7% | ||
| Q2 25 | — | -6.3% | ||
| Q1 25 | — | -16.6% | ||
| Q4 24 | -84.7% | -13.3% | ||
| Q3 24 | — | -15.4% | ||
| Q2 24 | — | -81.5% | ||
| Q1 24 | -132.6% | -27.4% |
| Q4 25 | 0.0% | 35.0% | ||
| Q3 25 | 0.0% | 4.3% | ||
| Q2 25 | 0.0% | 2.5% | ||
| Q1 25 | 0.0% | 1.7% | ||
| Q4 24 | 0.2% | 4.8% | ||
| Q3 24 | 0.0% | 2.0% | ||
| Q2 24 | 0.0% | 1.3% | ||
| Q1 24 | 0.6% | 5.3% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -1.62× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
KPTI
| Products | $32.1M | 94% |
| License And Other | $2.0M | 6% |
OUST
Segment breakdown not available.
